Combined therapy with telmisartan and spironolactone prevents early recurrence after catheter ablation for paroxysmal atrial fibrillation

Liang-qiao HU,Yu-mei XUE,Xian-zhang ZHAN,Hai DENG,Xian-hong FANG,Tian LIU,Shu-lin WU
DOI: https://doi.org/10.3969/j.issn.1673-6583.2014.02.018
2014-01-01
Abstract:Objective:To clarify the effects of telmisartan combined with spironolactone on early recurrence after catheter ablation in patients with paroxysmal atrial fibrillation (PAF). Methods:A total of 90 patients with PAF treated by catheter ablation were randomly assigned to control group (conventional treatment ) and therapy group (conventional treatment plus telmisartan and spironolactone ). 24h Holter monitoring, echocardiography, high-sensitivity C-reactive protein (hsCRP),and N terminal pro-brain natriuretic peptide (NT-proBNP)were examined at 1 and 3 months. Post-ablation recurrence was also recorded. Results:Post-ablation recurrence was recorded in 5 cases (11 .1 %)in therepy group and 12 cases(26.7%)in control group (P =0.44).Compared with control group,NT-proBNP in therapy group was decreased at 3 months (P =0.046).Variation in NT-proBNP (3 months vs baseline)in therapy group was significantly higher than that in control group (P =0.037). Conclusion:Telmisartan combined with spironolactone reduces early recurrence after catheter ablation of paroxysmal atrial fibrillation,and is associated with a decrease in the level of NT-proBNP at 3 months postoperation.
What problem does this paper attempt to address?